Genetic testing for nephrotic syndrome and FSGS in the era of next-generation sequencing

Kidney International

Volumn 85, Issue 5, 2014, Pages 1030-1038

  Brown, Elizabeth J ^a   Pollak, Martin R ^b   Barua, Moumita ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Focal segmental glomerulosclerosis; Genetic renal disease; Nephritic syndrome

Indexed keywords

ALPHA ACTININ 4; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; NEPHRIN; PODOCIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; WT1 PROTEIN;

AFRICAN AMERICAN; ALPHA ACTININ 4 GENE; APOL1 GENE; AUTOSOMAL DOMINANT DISORDER; CONGENITAL NEPHROTIC SYNDROME; DENYS DRASH SYNDROME; DNA SEQUENCE; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; FRASIER SYNDROME; GENE; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; HIV ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INVERTED FORMIN 2 GENE; KIDNEY TRANSPLANTATION; LAMININ BETA 2 GENE; NEPHROBLASTOMA; NEPHROTIC SYNDROME; NEXT GENERATION SEQUENCING; NPHS1 GENE; NPHS2 GENE; PENETRANCE; PHOSPHOLIPASE C EPSILON GENE; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY C MEMBER 6 GENE; WILM TUMOR 1 GENE; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR;

AFRICAN AMERICANS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MUTATION; NEPHROTIC SYNDROME; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 84899943190     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.48     Document Type: Review

References (73)

1. Tennessen JA, O'Connor TD, Bamshad MJ et al. The promise and limitations of population exomics for human evolution studies. Genome Biol 2011; 12: 127.
2. Kestila M, Lenkkeri U, Mannikko M et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1: 575-582.
3. Huber TB, Benzing T. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 2005; 14: 211-216.
4. Boute N, Gribouval O, Roselli S et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24: 349-354.
5. Hinkes BG, Mucha B, Vlangos CN et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119: e907-e919.
6. Tsukaguchi H, Sudhakar A, Le TC et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002; 110: 1659-1666.
7. Benoit G, Machuca E, Nevo F et al. Analysis of recessive CD2AP and ACTN4 mutations in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2010; 25: 445-451.
8. Hinkes B, Vlangos C, Heeringa S et al. Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19: 365-371.
9. Weber S, Gribouval O, Esquivel EL et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66: 571-579.
10. Tonna SJ, Needham A, Polu K et al. NPHS2 variation in focal and segmental glomerulosclerosis. BMC Nephrol 2008; 9: 13.
11. Machuca E, Hummel A, Nevo F et al. Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant. Kidney Int 2009; 75: 727-735.
12. Santin S, Tazon-Vega B, Silva I et al. Clinical value of NPHS2 analysis in early-and adult-onset steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6: 344-354.
13. Ruf RG, Lichtenberger A, Karle SM et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15: 722-732.
14. Jungraithmayr TC, Hofer K, Cochat P et al. Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation. J Am Soc Nephrol 2011; 22: 579-585.
15. Roselli S, Gribouval O, Boute N et al. Podocin localizes in the kidney to the slit diaphragm area. Am J Pathol 2002; 160: 131-139.
16. Schwarz K, Simons M, Reiser J et al. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001; 108: 1621-1629.
17. Santin S, Bullich G, Tazon-Vega B et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6: 1139-1148.
18. Machuca E, Benoit G, Nevo F et al. Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome. J Am Soc Nephrol 2010; 21: 1209-1217.
19. Caridi G, Bertelli R, Di Duca M et al. Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 2003; 14: 1278-1286.
20. Philippe A, Weber S, Esquivel EL et al. A missense mutation in podocin leads to early and severe renal disease in mice. Kidney Int 2008; 73: 1038-1047.
21. Santin S, Garcia-Maset R, Ruiz P et al. Nephrin mutations cause childhoodand adult-onset focal segmental glomerulosclerosis. Kidney Int 2009; 76: 1268-1276.
22. Pelletier J, Bruening W, Li FP et al. WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 1991; 353: 431-434.
23. Barbaux S, Niaudet P, Gubler MC et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997; 17: 467-470.
24. Ruf RG, Schultheiss M, Lichtenberger A et al. Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. Kidney Int 2004; 66: 564-570.
25. Mucha B, Ozaltin F, Hinkes BG et al. Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and Pediatr Res 2006; 59: 325-331.
26. Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol 2006; 21: 1653-1660.
27. Chernin G, Vega-Warner V, Schoeb DS et al. Genotype/phenotype correlation in nephrotic syndrome caused by WT1 mutations. Clin J Am Soc Nephrol 2010; 5: 1655-1662.
28. Jeanpierre C, Denamur E, Henry I et al. Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 1998; 62: 824-833.
29. Boyer O, Benoit G, Gribouval O et al. Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. J Med Genet 2010; 47: 445-452.
30. Al-Hamed MH, Al-Sabban E, Al-Mojalli H et al. A molecular genetic analysis of childhood nephrotic syndrome in a cohort of Saudi Arabian families. J Hum Genet 2013; 58: 480-489.
31. McCarthy HJ, Bierzynska A, Wherlock M et al. Simultaneous sequencing of 24 genes associated with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2013; 8: 637-648.
32. Mbarek IB, Abroug S, Omezzine A et al. Novel mutations in steroidresistant nephrotic syndrome diagnosed in Tunisian children. Pediatr Nephrol 2011; 26: 241-249.
33. Lehnhardt A, Lama A, Amann K et al. Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR. Pediatr Nephrol 2012; 27: 865-868.
34. Matejas V, Hinkes B, Alkandari F et al. Mutations in the human laminin beta2 (LAMB2) gene and the associated phenotypic spectrum. Hum Mutat 2010; 31: 992-1002.
35. Ovunc B, Otto EA, Vega-Warner V et al. Exome sequencing reveals cubilin mutation as a single-gene cause of proteinuria. J Am Soc Nephrol 2011; 22: 1815-1820.
36. Mele C, Iatropoulos P, Donadelli R et al. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med 2011; 365: 295-306.
37. Sanna-Cherchi S, Burgess KE, Nees SN et al. Exome sequencing identified MYO1E and NEIL1 as candidate genes for human autosomal recessive steroid-resistant nephrotic syndrome. Kidney Int 2011; 80: 389-396.
38. Gee HY, Saisawat P, Ashraf S et al. ARHGDIA mutations cause nephrotic syndrome via defective RHO GTPase signaling. J Clin Invest 2013; 123: 3243-3253.
39. Gupta IR, Baldwin C, Auguste D et al. ARHGDIA: a novel gene implicated in nephrotic syndrome. J Med Genet 2013; 50: 330-338.
40. Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24: 251-256.
41. Winn MP, Conlon PJ, Lynn KL et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308: 1801-1804.
42. Brown EJ, Schlondorff JS, Becker DJ et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42: 72-76.
43. Boyer O, Nevo F, Plaisier E et al. INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. N Engl J Med 2011; 365: 2377-2388.
44. Barua M, Brown EJ, Charoonratana VT et al. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int 2013; 83: 316-322.
45. Weins A, Kenlan P, Herbert S et al. Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 2005; 16: 3694-3701.
46. Reiser J, Polu KR, Moller CC et al. TRPC6 is a glomerular slit diaphragmassociated channel required for normal renal function. Nat Genet 2005; 37: 739-744.
47. Boyer O, Benoit G, Gribouval O et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 239-245.
48. Gbadegesin RA, Lavin PJ, Hall G et al. Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis. Kidney Int 2012; 81: 94-99.
49. Kopp JB, Smith MW, Nelson GW et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40: 1175-1184.
50. Kao WH, Klag MJ, Meoni LA et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40: 1185-1192.
51. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845.
52. Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350.
53. Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137.
54. Friedman DJ, Kozlitina J, Genovese G et al. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011; 22: 2098-2105.
55. Reeves-Daniel AM, DePalma JA, Bleyer AJ et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011; 11: 1025-1030.
56. Lee BT, Kumar V, Williams TA et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012; 12: 1924-1928.
57. Hildebrandt F. Genetic kidney diseases. Lancet 2010; 375: 1287-1295.
58. Buscher AK, Kranz B, Buscher R et al. Immunosuppression and renal outcome in congenital and pediatric steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2010; 5: 2075-2084.
59. Heeringa SF, Vlangos CN, Chernin G et al. Thirteen novel NPHS1 mutations in a large cohort of children with congenital nephrotic syndrome. Nephrol Dial Transplant 2008; 23: 3527-3533.
60. Hinkes B, Wiggins RC, Gbadegesin R et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38: 1397-1405.
61. Santin S, Ars E, Rossetti S et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009; 24: 3089-3096.
62. KDIGO clinical practice guildelines for glomerulonephritis. Kidney Int Suppl 2012; 2: 139-274.
63. Thusberg J, Olatubosun A, Vihinen M. Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 2011; 32: 358-368.
64. Al-Romaih KI, Genovese G, Al-Mojalli H et al. Genetic diagnosis in consanguineous families with kidney disease by homozygosity mapping coupled with whole-exome sequencing. Am J Kidney Dis 2011; 58: 186-195.
65. Otto EA, Ramaswami G, Janssen S et al. Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. J Med Genet 2011; 48: 105-116.
66. DePristo MA, Banks E, Poplin R et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
67. Mamanova L, Coffey AJ, Scott CE et al. Target-enrichment strategies for next-generation sequencing. Nat Methods 2010; 7: 111-118.
68. Loman NJ, Misra RV, Dallman TJ et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30: 434-439.
69. Ong FS, Lin JC, Das K et al. Translational utility of next-generation sequencing. Genomics 2013; 102: 137-139.
70. Gargis AS, Kalman L, Berry MW et al. Assuring the quality of nextgeneration sequencing in clinical laboratory practice. Nat Biotechnol 2012; 30: 1033-1036.
71. Sim NL, Kumar P, Hu J et al. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012; 40: W452-W457.
72. Adzhubei IA, Schmidt S, Peshkin L et al. A method and server for predicting damaging missense mutations. Nat Methods 2010; 7: 248-249.
73. Flannick J, Beer NL, Bick AG et al. Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet 2013; 45: 1380-1385.